Rhythm Pharmaceuticals, Inc. (RYTM) Balance Sheet

The shift from a cash-heavy asset base toward a thinner liquidity position indicates the company is funding operating losses from its reserves. Equity has also contracted from its 2025 peak of $295.7M to $201.5M, which reflects accumulated losses flowing through the balance sheet. Investors should monitor whether the next financing event occurs before liquidity becomes a binding constraint.

Cash covers roughly one quarter of net loss at the most recent burn rate, which is a thin margin for a commercial-stage company with ongoing R&D and launch costs. The current ratio of 2.78 remains adequate on paper but has declined steadily from 6.53 in Q2 2024, indicating shrinking short-term coverage. The position appears to depend on near-term capital raises or partnership proceeds, a dependency that warrants close watch.

Negligible borrowings mean refinancing risk is low and interest burden does not weigh on cash flow. The balance sheet's vulnerability therefore stems from operating losses and cash consumption rather than from obligations to creditors. This lack of leverage gives management flexibility, though it also means that equity dilution, rather than debt, is the more likely financing route.

The scale of the accumulated deficit relative to current equity signals that historical capital has been consumed by operations over many years. Stock-based compensation of $25.0M in the latest quarter adds to the economic cost borne by shareholders, even though it is non-cash. Continued losses suggest further equity issuance may be needed, which would dilute existing holders.

Deferred revenue has fallen to negligible levels, so the balance sheet provides no meaningful signal of contracted future revenue beyond recognized sales. Forward demand must instead be assessed through prescription trends and payer coverage, which are not captured in these balance sheet figures. Investors should not read the absence of deferred revenue as a negative signal by itself, but it removes a potential source of working capital support.